MARKET

CRVS

CRVS

Corvus Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.900
-0.110
-2.74%
Closed 16:00 08/12 EDT
OPEN
4.000
PREV CLOSE
4.010
HIGH
4.020
LOW
3.845
VOLUME
300.53K
TURNOVER
--
52 WEEK HIGH
6.88
52 WEEK LOW
1.010
MARKET CAP
109.34M
P/E (TTM)
-2.5153
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CRVS stock price target is 9.20 with a high estimate of 15.00 and a low estimate of 6.00.

EPS

CRVS News

More
Corvus Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
BURLINGAME, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference. The presentation will
GlobeNewswire · 08/04 20:05
Corvus Pharmaceuticals Q2 EPS $(0.36) Misses $(0.28) Estimate
Corvus Pharmaceuticals (NASDAQ:CRVS) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.28) by 28.57 percent. This is a 18.18 percent increase over losses of $(0.44) per
Benzinga · 07/30 20:05
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
Provides Update on CPI-006 Phase 1 COVID-19 Study Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today provide
GlobeNewswire · 07/30 20:02
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 07/30 12:09
CBAY, TEAM, MDRX and SHAK among after-hours movers
Seeking Alpha · 07/30 04:00
Corvus Pharmaceuticals EPS misses by $0.06
Seeking Alpha · 07/30 04:00
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2020 Financial Results on July 30, 2020
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a co
GlobeNewswire · 07/23 12:30
3 “Strong Buy” Healthcare Stocks Under $5 That Could Double (Or More)
The healthcare sector took its place among the winners this year, rising 21%, compared to the S&P 500’s 0.5% growth. The bottom-line for investors? Wall Street’s focus is on the healthcare space, locking in on biotechs in particular.It should be noted that the
TipRanks · 07/20 19:30

Industry

Biotechnology & Medical Research
+0.70%
Pharmaceuticals & Medical Research
+1.61%

Hot Stocks

Symbol
Price
%Change

About CRVS

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.
More

Webull offers kinds of Corvus Pharmaceuticals Inc stock information, including NASDAQ:CRVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRVS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRVS stock methods without spending real money on the virtual paper trading platform.